VanEck Pharmaceutical ETF (NASDAQ:PPH – Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,970,000 shares, a growth of 18.0% from the August 15th total of 1,670,000 shares. Based on an average trading volume of 141,200 shares, the days-to-cover ratio is presently 14.0 days.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans acquired a new position in shares of VanEck Pharmaceutical ETF during the second quarter valued at about $16,088,000. Northwestern Mutual Wealth Management Co. boosted its stake in VanEck Pharmaceutical ETF by 1.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 160,039 shares of the company’s stock valued at $14,641,000 after purchasing an additional 2,694 shares during the last quarter. Financial Partners Group Inc bought a new stake in VanEck Pharmaceutical ETF during the 2nd quarter worth approximately $8,701,000. J.Safra Asset Management Corp raised its stake in shares of VanEck Pharmaceutical ETF by 5.9% in the second quarter. J.Safra Asset Management Corp now owns 73,609 shares of the company’s stock worth $6,734,000 after purchasing an additional 4,084 shares during the last quarter. Finally, Bricktown Capital LLC bought a new position in shares of VanEck Pharmaceutical ETF in the second quarter valued at approximately $5,904,000.
VanEck Pharmaceutical ETF Trading Down 0.7 %
PPH traded down $0.71 on Tuesday, reaching $97.59. The stock had a trading volume of 52,985 shares, compared to its average volume of 138,537. The firm has a 50-day moving average of $95.08 and a 200-day moving average of $91.50. VanEck Pharmaceutical ETF has a fifty-two week low of $74.05 and a fifty-two week high of $99.51. The company has a market capitalization of $657.76 million, a price-to-earnings ratio of 21.04 and a beta of 0.72.
VanEck Pharmaceutical ETF Cuts Dividend
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Quiet Period Expirations Explained
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
- Insider Trades May Not Tell You What You Think
- What Buybacks and Lower Rates Could Mean for Restaurant Brands
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.